Bioequivalence Clinical Trial
Official title:
A Randomised, Double-blind, Single-dose, Parallel-group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of CinnoRA® (Produced by CinnaGen CO.) and Humira® (the Reference Drug, Produced by AbbVie Inc.)
This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate
CinnoRA® relative to adalimumab reference product (Humira®) and evaluate safety and
tolerability of CinnoRA®, in a parallel fashion in healthy volunteers after administration of
a single dose (40 mg) of adalimumab.
The primary objective of this study is to demonstrate that the PK of CinnoRA® is similar to
its originator, Humira®, as assessed by the area under the serum concentration time curve
(AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax.
The secondary objectives of the study are:
- To further compare the PK of CinnoRA® and Humira®.
- To assess the safety of CinnoRA®.
This is a single-dose trial with one administration of each product (CinnoRA® and Humira®).
Each subject will participate in one treatment period, and will be randomised to receive
CinnoRA® or Humira® in a parallel fashion. The subjects will be closely monitored during the
following 24 hours (h), and will be allowed to leave the site in the next morning post
evaluation and blood samples will be collected prior to and at the following time points
after the dose: 4, 8, 12 and 24 hours post-dose (on day 2). The subjects will be requested to
visit the trial site on days 3, 4, 5, 6, 7, 8, 9, 12, 15, 22, 29, 36, 43, 50, 57, 63 and 71
after dose for blood sampling and evaluation of safety variable and tolerability.
Before initiation, the trial is reviewed by food and drug administration of Iran. The
protocol, case report form (CRF), information for subjects and informed consent form are
submitted to the ethics committees responsible for review and approval purposes, according to
national regulatory guidelines.
In this study, no subject is recruited without an informed consent. All the informed consent
forms which are signed by the subjects have two copies so that subjects could receive a copy
of it.
This is a single-dose trial with one administration of each product (CinnoRA® and Humira®).
74 (group A=37, group B=37) eligible subjects have been planned to enter to the study. All of
whom are aged between 18 and 45 years. Subjects' randomization was done, using permuted block
randomization method. Both groups received 40 mg of either of the drugs as a single
subcutaneous injection. The injection method, injection pens and cartridges were totally the
same in both groups. The primary objective of this study is to demonstrate that the PK of
CinnoRA® is similar to its originator, Humira®, as assessed by the area under the serum
concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax.
Secondary objectives include assessment of the time to Cmax (tmax), AUC from time 0 to the
last quantifiable concentration (AUClast) of CinnoRA® compared with Humira®, as well as
evaluation of safety and tolerability. The safety endpoints of the trial are to evaluate the
incidence of reported adverse effects, detecting changes in vital signs, clinical laboratory
tests (hematologic, biochemistry, urine analysis and urine culture tests) and ECG.
Determination of sample size:
An equivalence test of means AUCinf using two one-sided tests on data from a parallel-group
design with sample sizes of 37 in the reference group and 37 in the treatment group achieves
81% power at a 10% significance level when the true ratio of the means AUCinf is 1.00, the
coefficient of variation on the original, unlogged scale is 0.38, and the equivalence limits
of the mean ratio AUCinf are 0.80 and 1.25.
DATA QUALITY ASSURANCE:
CinnaGen Company conducts clinical trials according to procedures that incorporate the
ethical principles of GCP. Accurate and reliable data collection was assured by verification
and cross-check of the CRFs against the subject's records by clinical monitors (source
document verification was performed), and the maintenance of a drug-dispensing log by the
center. A comprehensive validation check program was used to verify the data, and discrepancy
reports were generated accordingly for resolution by the investigator.
Blinding:
This is a double-blind trial. During the clinical phase of the trial, neither the subjects
nor the site personnel are aware of the identity (CinnoRA® and Humira®) of the treatments
administered. However, there is an unblinded person who receives the randomisation list and
dispenses the trial drugs according to the list. The unblinded person is not otherwise
participate in the execution of the trial. The randomisation list determines the dispensing
order of the trial products for each subject and only the randomisation number appear on the
sample collection logs, as well as, on the sample aliquots delivered to the bioanalytical
laboratory. Thus, the personnel responsible for analysing the PK samples are also be blinded.
Randomisation envelopes are stored in the ISF, in a locked cabinet. In a case of emergency,
the code of an individual subject may be opened and the reasons for opening will be
documented and the subject will be discontinued from the trial
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03705533 -
Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State
|
Phase 1 | |
Completed |
NCT04938856 -
Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03646331 -
Bioequivalence of Imeglimin Tablet Formulations
|
Phase 1 | |
Completed |
NCT04564456 -
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05197517 -
Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition
|
Phase 1 | |
Completed |
NCT03702894 -
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Withdrawn |
NCT02894515 -
Bioequivalence Study of Idalopirdine in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03018015 -
Ibuprofen Bioavailability Trial With Oral Single Dose Administration.
|
Phase 1 | |
Completed |
NCT02206295 -
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
|
Phase 1 | |
Completed |
NCT01331993 -
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
|
Phase 1 | |
Completed |
NCT01260805 -
A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
|
Phase 1 | |
Recruiting |
NCT06066112 -
Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
|
Phase 1 | |
Completed |
NCT05477810 -
Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions
|
Early Phase 1 | |
Completed |
NCT04546256 -
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05083325 -
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
|
Phase 1 | |
Completed |
NCT05061901 -
Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT04138888 -
A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT05145621 -
Oral Bio-equivalence Study
|
Phase 1 | |
Completed |
NCT06124560 -
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
|
Phase 1 | |
Completed |
NCT03340753 -
Bioavailability of KBP-5074 Tablet vs Capsule Formulations
|
Phase 1 |